Bremelanotide and HSDD: What the Clinical Trials Showed

The trial frame

This page summarizes clinical evidence in premenopausal women. It is not a treatment guide. It does not reproduce administration schedules. Trial numbers are not turned into instructions.

Phase 2: dose finding

Clayton and colleagues published a 2016 randomized, placebo-controlled dose-finding trial in premenopausal women with female sexual dysfunctions. The registry record is NCT01382719. The registry lists 612 participants. The published efficacy population was 327.^1,2

That trial informs a development program. It is not the pair of trials that carries the Phase 3 label. A size difference between the registry and the published paper is stated here; it is not hidden.

Phase 3: RECONNECT

Kingsberg and colleagues published two randomized, double-blind, placebo-controlled Phase 3 trials in 2019. The registry records are NCT02333071 and NCT02338960. The randomized total was 1,267 women.^3,4,5

The population was premenopausal women with acquired, generalized HSDD. That cut-off matters. It is not generalized to postmenopause, to men, or to “enhancing performance.”^3,6

Trial table

The three outcome concepts

The label reports statistically significant treatment differences on both co-primary measures. It also reports no significant difference in the change in the number of satisfying sexual events. A summary that keeps only the co-primaries is a cut.⁶

Evidence quality and independent critique

Statistical significance is not, by itself, a large clinical effect. Spielmans and Ellefson published a 2024 independent analysis that questions the magnitude and measurement properties of several RECONNECT outcomes. That critique does not overturn FDA approval. It places the primary trials next to a later methodological reading.^7,10

Long-term extension

Simon and colleagues published long-term safety and efficacy. The extension was open-label, not placebo-controlled. Participants who had completed the core trial could enroll. An open-label extension finding is not equivalent to the randomized Phase 3 evidence.⁸

Patient-experience study

There are exit surveys and interviews from RECONNECT participants. That material helps describe reported experience. It is not an independent efficacy RCT.⁹

RECONNECT’s co-primaries were measured with the FSFI desire domain and with item 13 of the FSDS-DAO, which focuses on distress. Those instruments are the language of the trials. They are not translated here into a use instruction or a promise of “broad sexual improvement.” One domain can move and another endpoint, satisfying sexual events, can fail to move.^3,6

That asymmetry is the fact most generic summaries omit. A reader can leave a commercial recap believing Phase 3 showed uniform improvement. The label does not say that. It reports a difference in desire, a difference in distress, and no significant difference in the number of satisfying sexual events. The three concepts travel together or the summary is incomplete.⁶

The Spielmans and Ellefson critique is read after that frame, not before. It is not used to erase approval or to declare that the trials “do not exist.” It is used to remember that a statistical difference has a magnitude, measurement properties, and a population context. An independent analysis can question those pieces and still leave intact the regulatory fact that Vyleesi was approved.^7,10

The open-label extension and the exit interviews occupy another shelf. Someone who completed the core trial could continue in a design without placebo. That informs persistence and reported experience. It does not replicate the control that carries RECONNECT. An open finding is not averaged with a randomized co-primary to invent a “general effect.”^8,9

This package is also not exported to a research vial. The trials administered the clinical program that later supports the approved product. Peptra was not an arm of those studies. An HPLC and intact-mass certificate does not inherit a co-primary. Clinical evidence stays clinical. Analytical documentation stays analytical.

Clayton’s Phase 2 occupies an earlier place, not an equivalent one. It was a randomized dose-finding trial in premenopausal women. The registry lists 612 participants; the published paper analyzes 327 in the efficacy population. That figure difference is stated so that no one turns the registry number into the population that carries the label. The Phase 3 pair is another design, another question, and another size.^1,2

RECONNECT’s population was acquired, generalized HSDD in premenopausal women. Acquired is not lifelong. Generalized is not situational. Premenopausal is not postmenopausal. Those adjectives are not decoration. They are the cut-off that prevents writing “it works for desire” as if the trial had enrolled any adult.^3,6

That is why this page does not use Phase 3 to talk about men, sexual performance, or an RUO material. There is another page for research in men. There is another for the Vyleesi comparison. The job here is narrower: show what was measured, in whom, with what result, and what drops out when the summary becomes too clean.

There is a second temporal cut. The co-primaries are read in the context of the controlled trials. The open-label extension is read afterward, as follow-up without placebo. Exit interviews are read as experience, not as a second RCT. If those layers flatten into one sentence about “the studies showed benefit,” the reader loses the order of the evidence.^3,8,9

There is a third geographic and regulatory cut. RECONNECT supports a U.S. FDA indication. It does not, by itself, support an authorization in Mexico. It does not support a use outside the labeled population. And it does not support a third-party vial. The evidence is real. The reach of that evidence is narrower than the headline that usually circulates.^6,10

What this page does not say

• It does not say bremelanotide “raises libido in everyone.”
• It does not turn Phase 3 into broad improvement across all sexual outcomes.
• It does not treat the open-label extension as a second Phase 3 pair.
• It does not apply these results to a Peptra research vial.

A later editor who writes “Phase 3 showed improvement in sexual outcomes” will have failed this page’s test. Desire, distress, and the absence of a significant difference in satisfying sexual events must all remain. If the third is omitted because it is less favorable, the text stops being an evidence summary and becomes a cut.⁶

Next reading

• Read the labeled indication, limits, and safety
• See the research in men, separately
• Back to the research hub